Autem Therapeutics

About Autem Therapeutics

Formerly known as Autem Medical, Autem Therapeutics is a privately held, venture capital-backed bioelectric technology company focused on oncology. The company was founded in 2017 by Frederico Costa, a medical oncologist, and is now led by co-founder and CEO Michael Choukas, an executive with extensive experience in global strategy and clinical development. Based in Hanover, New Hampshire, the firm is developing a non-invasive, non-toxic treatment platform for various solid tumor cancers, with a primary focus on Hepatocellular Carcinoma (HCC), also known as liver cancer.

The company's core product is the AutEMsys™ therapy, a bioelectric platform that has received FDA breakthrough designation. This system delivers personalized, amplitude-modulated electromagnetic frequencies to patients systemically. The underlying principle is to re-synchronize the metabolic cycles of cancer cells, which are desynchronized from healthy cells, by balancing their electrophysiological properties. By delivering low-level electromagnetic frequencies, the therapy aims to normalize the cancer cells' metabolism and improve energy efficiency, which initial studies on 66 HCC patients suggest may lead to shrinking tumors, extended survival, and an enhanced quality of life. The treatment is designed to be accessible, as the equipment does not require refrigeration or a complex distribution infrastructure, and can treat multiple patients per month. However, the device has not yet received full regulatory approval and is not commercially available.

Autem Therapeutics' business model revolves around the development and future commercialization of its proprietary bioelectric technology. The company is venture-backed, having raised $13.5M to date, with a significant Series A-1 financing round of $10 million in June 2022, led by Zentynel Frontier Investments. These funds are allocated to the completion of the next-generation AutEMsys™ system, securing regulatory approvals in the US, Europe, and Latin America, and initiating a pivotal clinical trial for HCC.